• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    11/3/23 1:31:00 PM ET
    $ACXP
    $AGL
    $COCH
    $DRIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Misc Health and Biotechnology Services
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • Evelo Biosciences (NASDAQ:EVLO) stock rose 48.5% to $0.46 during Friday's regular session. Trading volume for Evelo Biosciences's stock is 4.0 million as of 13:30 EST. This is 1695.5% of its average full-day volume over the last 100 days. The company's market cap stands at $8.6 million.
    • Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 45.81% to $3.13. As of 13:30 EST, Werewolf Therapeutics's stock is trading at a volume of 27.1 million, which is 24005.4% of its average full-day volume over the last 100 days. The company's market cap stands at $111.7 million.
    • DarioHealth (NASDAQ:DRIO) shares rose 32.67% to $1.34. Trading volume for this security as of 13:30 EST is 703.0K, which is 444.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $36.4 million. The company's, Q3 earnings came out yesterday.
    • Kazia Therapeutics (NASDAQ:KZIA) shares rose 31.22% to $0.52. The current volume of 411.1K shares is 892.9% of Kazia Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $12.4 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares increased by 29.91% to $0.8. Dermata Therapeutics's stock is trading at a volume of 320.6K shares as of 13:30 EST. This is 278.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock rose 29.9% to $0.34. Trading volume for this security as of 13:30 EST is 50.7 million, which is 88.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $56.4 million.

    Losers

    • NexImmune (NASDAQ:NEXI) stock declined by 32.4% to $2.51 during Friday's regular session. Trading volume for this security as of 13:30 EST is 294.2K, which is 4972.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Panbela Therapeutics (NASDAQ:PBLA) shares fell 26.83% to $0.7. The current volume of 3.5 million shares is 384.2% of Panbela Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $2.0 million.
    • Agilon Health (NYSE:AGL) stock fell 16.29% to $14.14. The current volume of 11.6 million shares is 530.9% of Agilon Health's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $5.7 billion. As per the press release, Q3 earnings came out yesterday.
    • Virios Therapeutics (NASDAQ:VIRI) stock fell 15.7% to $0.68. Virios Therapeutics's stock is trading at a volume of 993.8K shares as of 13:30 EST. This is 169.8% of its average full-day volume over the last 100 days. The company's market cap stands at $13.1 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock fell 13.95% to $3.27. Trading volume for this security as of 13:30 EST is 785.7K, which is 114.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $42.5 million.
    • Envoy Medical (NASDAQ:COCH) shares declined by 13.94% to $1.05. The market value of their outstanding shares is at $22.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $AGL
    $COCH
    $DRIO

    CompanyDatePrice TargetRatingAnalyst
    Werewolf Therapeutics Inc.
    $HOWL
    12/19/2025$1.00Outperform → Neutral
    Wedbush
    agilon health inc.
    $AGL
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    agilon health inc.
    $AGL
    8/6/2025$1.00Buy → Neutral
    Citigroup
    agilon health inc.
    $AGL
    4/25/2025$5.00Neutral → Buy
    Citigroup
    agilon health inc.
    $AGL
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    Kazia Therapeutics Limited
    $KZIA
    2/6/2025$3.00Buy
    Maxim Group
    DarioHealth Corp.
    $DRIO
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    agilon health inc.
    $AGL
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    More analyst ratings

    $ACXP
    $AGL
    $COCH
    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Markets Officer Shaker Benjamin bought $301,050 worth of shares (500,000 units at $0.60), increasing direct ownership by 58% to 1,367,674 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/3/26 5:28:28 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    SEC Filings

    View All

    Acurx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    3/9/26 8:59:44 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    2/27/26 9:11:14 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by agilon health inc.

    10-K - agilon health, inc. (0001831097) (Filer)

    2/25/26 4:12:09 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

    Findings reinforce that engagement data provide clinical signals directly impacting ROIAnalysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curveNEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform.  The observational study, titled "Machine learning and engagement insights for personalized blood glucose management," analyzed real-world data from 22,414

    3/10/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

    Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical TrialsAcurx is launching a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to oneWhen coupled with IBZ Phase 2 results of being highly effective (96% clinical cure of 26 patients) in treating acute CDI with no recurrence in patients while sparing the gut microbiome, this new trial will position IBZ as a candidate to be the first agent to demonstrate clinical success in both the treatment of CDI and the prevention of rCDIIn a Phase 2 trial, all

    3/9/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management

    As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world successGiven GLP-1 medication expense is one of the fastest-growing cost drivers for payers, Dario enables real-world patient adherence to deliver better long term health outcomes and reduced spending for clients resulting in higher ROI NEW YORK, March 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced increasing employer and health plan demand for its oral GLP-1 digital health solution, which is purpose-

    3/3/26 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Markets Officer Shaker Benjamin bought $301,050 worth of shares (500,000 units at $0.60), increasing direct ownership by 58% to 1,367,674 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/3/26 5:28:28 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Werewolf Therapeutics downgraded by Wedbush with a new price target

    Wedbush downgraded Werewolf Therapeutics from Outperform to Neutral and set a new price target of $1.00

    12/19/25 9:28:37 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agilon Health downgraded by Bernstein with a new price target

    Bernstein downgraded Agilon Health from Outperform to Mkt Perform and set a new price target of $1.40

    8/20/25 8:21:47 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health downgraded by Citigroup with a new price target

    Citigroup downgraded Agilon Health from Buy to Neutral and set a new price target of $1.00

    8/6/25 7:57:52 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

    WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. "Steve brings deep experience in strategic transactions to Werewolf at this critical tim

    4/17/25 8:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/14/24 4:19:36 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AGL
    $COCH
    $DRIO
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Wednesday, February 25, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 868078. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the cal

    1/22/26 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    DarioHealth Reports Third Quarter 2025 Financial and Operating Results

    Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 millionExceeded 2025 goal of 40 new signed accounts for 2026 revenue, with 45 new signed accounts to date—several already contributing to 2025 results; average employer customer size nearly doubled what was projectedStrong business fundamentals in the third quarter including GAAP gross margin increase to 60%, 7 consecutive quarters of 80%+ non-GAAP gross margins on core

    11/13/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care